Psoriatic Arthritis Treatment Market By Molecule Type (Monoclonal Antibodies, Fusion Proteins, Small Molecules, Biosimilars, Conventional Synthetic Drugs (csDMARDs)), By Mechanism of Action (TNF-α Inhibitors, IL-17 Inhibitors, IL-12/23 Inhibitor, IL-23 Inhibitors, JAK Inhibitors, PDE4 Inhibitor, Conventional DMARDs, NSAIDs & Corticosteroids), By Route of Administration (Subcutaneous (SC) Injection, Intravenous (IV) Infusion, Oral, Intra-articular), By Phenotype (Peripheral Arthritis-predominant, Axial PsA, Enthesitis-dominant, Dactylitis-dominant, Nail Disease Involvement, Psoriasis with Joint Involvement), By End-user (Hospitals & Hospital Pharmacies, Specialty Clinics, Ambulatory Infusion Centers, Self-administration Settings, Retail & Online Pharmacies, Other), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles And Market Forecast, 2025–2035

---

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & Forecast Parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Psoriatic Arthritis Treatment Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. How is the rising global prevalence of psoriatic arthritis fueling treatment market expansion?

3.2.2. Why does increasing adoption of biologics and targeted therapies boost therapeutic revenue growth worldwide?

3.2.3. How do supportive reimbursement policies enhance patient access to advanced arthritis treatment options?

3.3. Key industry pitfalls & challenges

3.3.1. Why does high treatment cost restrict access to biologics among lower-income patients?

3.3.2. How do stringent regulatory requirements delay approvals of novel psoriatic arthritis drug candidates?

3.3.3. Why is limited awareness in developing nations slowing early diagnosis and effective treatment adoption?

3.4. Market Opportunities

3.4.1. How will biosimilar drug introductions expand affordability and market penetration in emerging countries?

3.4.2. Why does advancing the precision medicine approach open avenues for highly personalized arthritis treatment strategies?

3.4.3. How can strategic collaborations accelerate innovation and market expansion across global psoriatic arthritis therapies?

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Psoriatic Arthritis Treatment Market, Molecule Type Segment Analysis

4.1. Overview of Dynamics

4.1.1. Market Revenue Share, By Molecule Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Monoclonal Antibodies

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Fusion Proteins

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Small Molecules Biosimilars

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Conventional Synthetic Drugs (csDMARDs)

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Psoriatic Arthritis Treatment Market, Mechanism of Action Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Mechanism of Action, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. TNF-α Inhibitors

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. IL-17 Inhibitors

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. IL-12/23 Inhibitor

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. IL-23 Inhibitors

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. JAK Inhibitors

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.7. PDE4 Inhibitor

5.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.8. Conventional DMARDs

5.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.9. NSAIDs & Corticosteroids

5.9.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Psoriatic Arthritis Treatment Market, Route of Administration Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Subcutaneous (SC) injection

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Intravenous (IV) infusion

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Oral

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Intra-articular

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Psoriatic Arthritis Treatment Market, Phenotype Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Phenotype, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Peripheral arthritis-predominant

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Axial PsA

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Enthesitis-dominant

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Dactylitis-dominant

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.6. Nail disease involvement

7.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.7. Psoriasis with joint involvement

7.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Psoriatic Arthritis Treatment Market, End-user Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By End-user, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Hospitals & Hospital Pharmacies

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Specialty Clinics

8.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.4. Ambulatory Infusion Centers

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.5. Self-administration settings

8.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.6. Retail & Online Pharmacies

8.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.7. Other

8.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. Psoriatic Arthritis Treatment Market, Region Segment Analysis

9.1. Overview

9.1.1. Global Market Revenue Share, By Region, 2025 & 2035

9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

9.2. North America

9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

9.2.2. North America Market Revenue, By Molecule Type, 2025-2035

9.2.3. North America Market Revenue, By Mechanism of Action, 2025-2035

9.2.4. North America Market Revenue, By Route of Administration, 2025-2035

9.2.5. North America Market Revenue, By Phenotype, 2025-2035

9.2.6. North America Market Revenue, By End-user, 2025-2035

9.2.7. The U.S.

9.2.7.1. U.S. Market Revenue, By Molecule Type, 2025-2035

9.2.7.2. U.S. Market Revenue, By Mechanism of Action, 2025-2035

9.2.7.3. U.S. Market Revenue, By Route of Administration, 2025-2035

9.2.7.4. U.S. Market Revenue, By Phenotype, 2025-2035

9.2.7.5. U.S. Market Revenue, By End-user, 2025-2035

9.2.8. Canada

9.2.8.1. Canada Market Revenue, By Molecule Type, 2025-2035

9.2.8.2. Canada Market Revenue, By Mechanism of Action, 2025-2035

9.2.8.3. Canada Market Revenue, By Route of Administration, 2025-2035

9.2.8.4. Canada Market Revenue, By Phenotype, 2025-2035

9.2.8.5. Canada Market Revenue, By End-user, 2025-2035

9.3. Europe

9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

9.3.2. Europe Market Revenue, By Molecule Type, 2025-2035

9.3.3. Europe Market Revenue, By Mechanism of Action, 2025-2035

9.3.4. Europe Market Revenue, By Route of Administration, 2025-2035

9.3.5. Europe Market Revenue, By Phenotype, 2025-2035

9.3.6. Europe Market Revenue, By End-user, 2025-2035

9.3.7. Germany

9.3.7.1. Germany Market Revenue, By Molecule Type, 2025-2035

9.3.7.2. Germany Market Revenue, By Mechanism of Action, 2025-2035

9.3.7.3. Germany Market Revenue, By Route of Administration, 2025-2035

9.3.7.4. Germany Market Revenue, By Phenotype, 2025-2035

9.3.7.5. Germany Market Revenue, By End-user, 2025-2035

9.3.8. France

9.3.8.1. France Market Revenue, By Molecule Type, 2025-2035

9.3.8.2. France Market Revenue, By Mechanism of Action, 2025-2035

9.3.8.3. France Market Revenue, By Route of Administration, 2025-2035

9.3.8.4. France Market Revenue, By Phenotype, 2025-2035

9.3.8.5. France Market Revenue, By End-user, 2025-2035

9.3.9. U.K.

9.3.9.1. U.K. Market Revenue, By Molecule Type, 2025-2035

9.3.9.2. U.K. Market Revenue, By Mechanism of Action, 2025-2035

9.3.9.3. U.K. Market Revenue, By Route of Administration, 2025-2035

9.3.9.4. U.K. Market Revenue, By Phenotype, 2025-2035

9.3.9.5. U.K. Market Revenue, By End-user, 2025-2035

9.3.10. Italy

9.3.10.1. Italy Market Revenue, By Molecule Type, 2025-2035

9.3.10.2. Italy Market Revenue, By Mechanism of Action, 2025-2035

9.3.10.3. Italy Market Revenue, By Route of Administration, 2025-2035

9.3.10.4. Italy Market Revenue, By Phenotype, 2025-2035

9.3.10.5. Italy Market Revenue, By End-user, 2025-2035

9.3.11. Spain

9.3.11.1. Spain Market Revenue, By Molecule Type, 2025-2035

9.3.11.2. Spain Market Revenue, By Mechanism of Action, 2025-2035

9.3.11.3. Spain Market Revenue, By Route of Administration, 2025-2035

9.3.11.4. Spain Market Revenue, By Phenotype, 2025-2035

9.3.11.5. Spain Market Revenue, By End-user, 2025-2035

9.3.12. Rest of Europe

9.3.12.1. Rest of Europe Market Revenue, By Molecule Type, 2025-2035

9.3.12.2. Rest of Europe Market Revenue, By Mechanism of Action, 2025-2035

9.3.12.3. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

9.3.12.4. Rest of Europe Market Revenue, By Phenotype, 2025-2035

9.3.12.5. Rest of Europe Market Revenue, By End-user, 2025-2035

9.4. Asia Pacific

9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

9.4.2. Asia Pacific Market Revenue, By Molecule Type, 2025-2035

9.4.3. Asia Pacific Market Revenue, By Mechanism of Action, 2025-2035

9.4.4. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.5. Asia Pacific Market Revenue, By Phenotype, 2025-2035

9.4.6. Asia Pacific Market Revenue, By End-user, 2025-2035

9.4.7. China

9.4.7.1. China Market Revenue, By Molecule Type, 2025-2035

9.4.7.2. China Market Revenue, By Mechanism of Action, 2025-2035

9.4.7.3. China Market Revenue, By Route of Administration, 2025-2035

9.4.7.4. China Market Revenue, By Phenotype, 2025-2035

9.4.7.5. China Market Revenue, By End-user, 2025-2035

9.4.8. Japan

9.4.8.1. Japan Market Revenue, By Molecule Type, 2025-2035

9.4.8.2. Japan Market Revenue, By Mechanism of Action, 2025-2035

9.4.8.3. Japan Market Revenue, By Route of Administration, 2025-2035

9.4.8.4. Japan Market Revenue, By Phenotype, 2025-2035

9.4.8.5. Japan Market Revenue, By End-user, 2025-2035

9.4.9. India

9.4.9.1. India Market Revenue, By Molecule Type, 2025-2035

9.4.9.2. India Market Revenue, By Mechanism of Action, 2025-2035

9.4.9.3. India Market Revenue, By Route of Administration, 2025-2035

9.4.9.4. India Market Revenue, By Phenotype, 2025-2035

9.4.9.5. India Market Revenue, By End-user, 2025-2035

9.4.10. Australia

9.4.10.1. Australia Market Revenue, By Molecule Type, 2025-2035

9.4.10.2. Australia Market Revenue, By Mechanism of Action, 2025-2035

9.4.10.3. Australia Market Revenue, By Route of Administration, 2025-2035

9.4.10.4. Australia Market Revenue, By Phenotype, 2025-2035

9.4.10.5. Australia Market Revenue, By End-user, 2025-2035

9.4.11. South Korea

9.4.11.1. South Korea Market Revenue, By Molecule Type, 2025-2035

9.4.11.2. South Korea Market Revenue, By Mechanism of Action, 2025-2035

9.4.11.3. South Korea Market Revenue, By Route of Administration, 2025-2035

9.4.11.4. South Korea Market Revenue, By Phenotype, 2025-2035

9.4.11.5. South Korea Market Revenue, By End-user, 2025-2035

9.4.12. Singapore

9.4.12.1. Singapore Market Revenue, By Molecule Type, 2025-2035

9.4.12.2. Singapore Market Revenue, By Mechanism of Action, 2025-2035

9.4.12.3. Singapore Market Revenue, By Route of Administration, 2025-2035

9.4.12.4. Singapore Market Revenue, By Phenotype, 2025-2035

9.4.12.5. Singapore Market Revenue, By End-user, 2025-2035

9.4.13. Rest of Asia Pacific

9.4.13.1. Rest of Asia Pacific Market Revenue, By Molecule Type, 2025-2035

9.4.13.2. Rest of Asia Pacific Market Revenue, By Mechanism of Action, 2025-2035

9.4.13.3. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.13.4. Rest of Asia Pacific Market Revenue, By Phenotype, 2025-2035

9.4.13.5. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

9.5. Latin America

9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

9.5.2. Latin America Market Revenue, By Molecule Type, 2025-2035

9.5.3. Latin America Market Revenue, By Mechanism of Action, 2025-2035

9.5.4. Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.5. Latin America Market Revenue, By Phenotype, 2025-2035

9.5.6. Latin America Market Revenue, By End-user, 2025-2035

9.5.7. Brazil

9.5.7.1. Brazil Market Revenue, By Molecule Type, 2025-2035

9.5.7.2. Brazil Market Revenue, By Mechanism of Action, 2025-2035

9.5.7.3. Brazil Market Revenue, By Route of Administration, 2025-2035

9.5.7.4. Brazil Market Revenue, By Phenotype, 2025-2035

9.5.7.5. Brazil Market Revenue, By End-user, 2025-2035

9.5.8. Argentina

9.5.8.1. Argentina Market Revenue, By Molecule Type, 2025-2035

9.5.8.2. Argentina Market Revenue, By Mechanism of Action, 2025-2035

9.5.8.3. Argentina Market Revenue, By Route of Administration, 2025-2035

9.5.8.4. Argentina Market Revenue, By Phenotype, 2025-2035

9.5.8.5. Argentina Market Revenue, By End-user, 2025-2035

9.5.9. Mexico

9.5.9.1. Mexico Market Revenue, By Molecule Type, 2025-2035

9.5.9.2. Mexico Market Revenue, By Mechanism of Action, 2025-2035

9.5.9.3. Mexico Market Revenue, By Route of Administration, 2025-2035

9.5.9.4. Mexico Market Revenue, By Phenotype, 2025-2035

9.5.9.5. Mexico Market Revenue, By End-user, 2025-2035

9.5.10. Rest of Latin America

9.5.10.1. Rest of Latin America Market Revenue, By Molecule Type, 2025-2035

9.5.10.2. Rest of Latin America Revenue, By Mechanism of Action, 2025-2035

9.5.10.3. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.10.4. Rest of Latin America Market Revenue, By Phenotype, 2025-2035

9.5.10.5. Rest of Latin America Market Revenue, By End-user, 2025-2035

9.6. MEA

9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

9.6.2. MEA Market Revenue, By Molecule Type, 2025-2035

9.6.3. MEA Market Revenue, By Mechanism of Action, 2025-2035

9.6.4. MEA Market Revenue, By Route of Administration, 2025-2035

9.6.5. MEA Market Revenue, By Phenotype, 2025-2035

9.6.6. MEA Market Revenue, By End-user, 2025-2035

9.6.7. GCC Countries

9.6.7.1. GCC Countries Market Revenue, By Molecule Type, 2025-2035

9.6.7.2. GCC Countries Market Revenue, By Mechanism of Action, 2025-2035

9.6.7.3. GCC Countries Market Revenue, By Route of Administration, 2025-2035

9.6.7.4. GCC Countries Market Revenue, By Phenotype, 2025-2035

9.6.7.5. GCC Countries Market Revenue, By End-user, 2025-2035

9.6.8. South Africa

9.6.8.1. South Africa Market Revenue, By Molecule Type, 2025-2035

9.6.8.2. South Africa Market Revenue, By Mechanism of Action, 2025-2035

9.6.8.3. South Africa Market Revenue, By Route of Administration, 2025-2035

9.6.8.4. South Africa Market Revenue, By Phenotype, 2025-2035

9.6.8.5. South Africa Market Revenue, By End-user, 2025-2035

9.6.9. Rest of Middle-East & Africa

9.6.9.1. Rest of Middle-East & Africa Market Revenue, By Molecule Type, 2025-2035

9.6.9.2. Rest of Middle-East & Africa Market Revenue, By Mechanism of Action, 2025-2035

9.6.9.3. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

9.6.9.4. Rest of Middle-East & Africa Market Revenue, By Phenotype, 2025-2035

9.6.9.5. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

10. Company Profile

10.1. AbbVie Inc.

10.1.1. Business Overview

10.1.2. Financial Performance

10.1.3. Product/Service Offerings

10.1.4. Strategies & recent developments

10.1.5. SWOT Analysis

10.2. Johnson & Johnson Services, Inc.

10.2.1. Business Overview

10.2.2. Financial Performance

10.2.3. Product/Service Offerings

10.2.4. Strategies & recent developments

10.2.5. SWOT Analysis

10.3. Novartis International AG

10.3.1. Business Overview

10.3.2. Financial Performance

10.3.3. Product/Service Offerings

10.3.4. Strategies & recent developments

10.3.5. SWOT Analysis

10.4. Eli Lilly and Company

10.4.1. Business Overview

10.4.2. Financial Performance

10.4.3. Product/Service Offerings

10.4.4. Strategies & recent developments

10.4.5. SWOT Analysis

10.5. Amgen Inc.

10.5.1. Business Overview

10.5.2. Financial Performance

10.5.3. Product/Service Offerings

10.5.4. Strategies & recent developments

10.5.5. SWOT Analysis

10.6. Pfizer Inc.

10.6.1. Business Overview

10.6.2. Financial Performance

10.6.3. Product/Service Offerings

10.6.4. Strategies & recent developments

10.6.5. SWOT Analysis

10.7. UCB S.A.

10.7.1. Business Overview

10.7.2. Financial Performance

10.7.3. Product/Service Offerings

10.7.4. Strategies & recent developments

10.7.5. SWOT Analysis

10.8. Bristol Myers Squibb Company

10.8.1. Business Overview

10.8.2. Financial Performance

10.8.3. Product/Service Offerings

10.8.4. Strategies & recent developments

10.8.5. SWOT Analysis

10.9. GlaxoSmithKline plc

10.9.1. Business Overview

10.9.2. Financial Performance

10.9.3. Product/Service Offerings

10.9.4. Strategies & recent developments

10.9.5. SWOT Analysis

10.10. Biogen Inc.

10.10.1. Business Overview

10.10.2. Financial Performance

10.10.3. Product/Service Offerings

10.10.4. Strategies & recent developments

10.10.5. SWOT Analysis

10.11. Gilead Sciences, Inc.

10.11.1. Business Overview

10.11.2. Financial Performance

10.11.3. Product/Service Offerings

10.11.4. Strategies & recent developments

10.11.5. SWOT Analysis

10.12. Sun Pharmaceutical Industries Ltd.

10.12.1. Business Overview

10.12.2. Financial Performance

10.12.3. Product/Service Offerings

10.12.4. Strategies & recent developments

10.12.5. SWOT Analysis

10.13. AstraZeneca plc

10.13.1. Business Overview

10.13.2. Financial Performance

10.13.3. Product/Service Offerings

10.13.4. Strategies & recent developments

10.13.5. SWOT Analysis

10.14. Takeda Pharmaceutical Company Limited

10.14.1. Business Overview

10.14.2. Financial Performance

10.14.3. Product/Service Offerings

10.14.4. Strategies & recent developments

10.14.5. SWOT Analysis

10.15. Enlivex Therapeutics Ltd.

10.15.1. Business Overview

10.15.2. Financial Performance

10.15.3. Product/Service Offerings

10.15.4. Strategies & recent developments

10.15.5. SWOT Analysis